Ernexa Therapeutics (ERNA) Stock Price, Financials & Analysis

Key Stats

Market Cap2.47 Mn

P/E-0.20

P/S36.90

Div. Yield0.00

Add ratio to table…

About

Ernexa Therapeutics Inc. is a preclinical stage synthetic allogeneic iMSC therapy company focused on developing off the shelf cell therapies for cancer and autoimmune diseases using induced pluripotent stem cell derived mesenchymal stem cells. The company generates revenue primarily through potential future product sales, licensing agreements, and collaborations, including upfront and milestone payments from partners such as Factor Bioscience Limited under its exclusive…

How Ernexa Therapeutics ranks

Ranked against the 668 companies in Pharmaceuticals and Biotechnology58 metrics · as of Oct 21, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −0.22xMedian 16.8x 8^th
P/FCFNegative free cash flow −0.30xMedian 18.3x 8^th
P/Operating cash flowNegative operating cash flow −0.30xMedian 17.0x 8^th
P/S 39.1xMedian 9.38x 25^th
P/B 0.82xMedian 2.17x 78^th
P/Tangible book 0.82xMedian 2.42x 81^st
EV/EBITDANet cash exceeds market value 0.18xMedian 15.7x Not meaningful —
EV/EBITNet cash exceeds market value 0.17xMedian 19.8x Not meaningful —
EV/RevenueNet cash exceeds market value −35.9xMedian 6.59x Not meaningful —
EV/FCFNet cash exceeds market value 0.27xMedian 19.2x Not meaningful —
EV/Operating cash flowNet cash exceeds market value 0.27xMedian 16.0x Not meaningful —
PEG (3Y EPS CAGR)Negative earnings 0.00Median 0.33 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) −86.9%Median 10.2% 6^th
Revenue CAGR (3Y) 40.8%Median 10.2% 76^th
Gross profit growth (1Y) —Median 10.6% No data —
Gross profit CAGR (3Y) —Median 10.7% No data —
Operating income growth (1Y) −35.3%Median 0.0% 27^th
Operating income CAGR (3Y) 15.6%Median 1.6% 67^th
Net income growth (1Y) 72.0%Median −5.1% 89^th
Net income CAGR (3Y) 17.4%Median −0.4% 70^th
EPS growth (1Y) −22.9%Median 21.0% 27^th
EPS CAGR (3Y) 44.7%Median 25.3% 73^rd
Operating cash flow growth (1Y) 38.8%Median 0.3% 80^th
Operating cash flow CAGR (3Y) 25.6%Median 2.4% 78^th
Free cash flow growth (1Y) 38.7%Median 0.3% 80^th
Free cash flow CAGR (3Y) 25.6%Median 3.3% 77^th

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin —Median 74.0% No data —
EBITDA margin <−10,000%Median −216% 3^rd
Operating margin <−10,000%Median −230% 4^th
Pretax margin <−10,000%Median −223% 6^th
Net margin <−10,000%Median −230% 5^th
FCF margin <−10,000%Median −168% 5^th
Operating cash flow margin <−10,000%Median −157% 5^th
Return on equity −244%Median −53.5% 10^th
Return on assets −145%Median −42.0% 13^th
Return on invested capital —Median −5.3% No data —
Return on capital employed −251%Median −46.0% 7^th
Asset turnover 0.01xMedian 0.18x 9^th
Cash conversion (OCF / net income)Net income is not positive 0.72xMedian 1.21x Not meaningful —
Stock comp / revenue 1,873%Median 27.5% 5^th

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets —Median 20.0% No data —
Debt / equity —Median 0.26x No data —
Net debt / EBITDA —Median 1.82x No data —
Debt / FCF —Median 3.03x No data —
Liabilities / assets 49.3%Median 32.8% 39^th
Equity / assets 50.7%Median 67.2% 39^th
Interest coverage —Median −10.1x No data —
Current ratio 2.01xMedian 4.48x 28^th
Quick ratio 1.71xMedian 3.72x 32^nd
Cash ratio 1.71xMedian 3.34x 36^th
Altman Z-score −62.7Median −0.62 4^th

Shareholder Returns

7 metrics · Cash returned through dividends and buybacks; a lower payout ranks higher

Dividend yield —Median 2.4% No dividend —
Net buyback yieldAbove 100% of market value −366%Median −3.3% Not meaningful —
Shareholder yieldAbove 100% of market value −366%Median −2.3% Not meaningful —
Payout ratio (earnings) —Median 50.9% No dividend —
Payout ratio (FCF) —Median 45.2% No dividend —
Dividend growth (1Y) —Median 3.9% No dividend —
Dividend CAGR (3Y) —Median 3.5% No dividend —

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,136.97 Bn	42.57	14.27	54.91 Bn
2	JNJ	Johnson & Johnson	619.72 Bn	29.46	6.33	49.04 Bn
3	ABBV	AbbVie Inc.	503.40 Bn	79.78	7.82	70.82 Bn
4	MRK	Merck & Co., Inc.	370.15 Bn	116.66	5.56	53.91 Bn
5	NVS	Novartis Ag	298.64 Bn	18.93	5.45	9.59 Bn
6	AZN	Astrazeneca Plc	261.07 Bn	24.99	4.45	32.35 Bn
7	AMGN	Amgen Inc	237.00 Bn	27.11	6.22	57.30 Bn
8	ERNA	Ernexa Therapeutics Inc.	0.00 Bn	-0.20	36.90	-

S.No.

Ticker

Company

Market Cap

P/E

P/S

Total Debt (Qtr)

LLY

ELI LILLY & Co

1,136.97 Bn

42.57

14.27

54.91 Bn

JNJ

Johnson & Johnson

619.72 Bn

29.46

6.33

49.04 Bn

ABBV

AbbVie Inc.

503.40 Bn

79.78

7.82

70.82 Bn

MRK

Merck & Co., Inc.

370.15 Bn

116.66

5.56

53.91 Bn

NVS

Novartis Ag

298.64 Bn

18.93

5.45

9.59 Bn

AZN

Astrazeneca Plc

261.07 Bn

24.99

4.45

32.35 Bn

AMGN

Amgen Inc

237.00 Bn

27.11

6.22

57.30 Bn

ERNA

Ernexa Therapeutics Inc.

0.00 Bn

-0.20

36.90

Ernexa Therapeutics ERNA

About

Products and Services Breakdown of Revenue (2020)

Statement Geographical Breakdown of Revenue (2020)

How Ernexa Therapeutics ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Ernexa Therapeutics ERNA

About

Products and Services Breakdown of Revenue (2020)

Statement Geographical Breakdown of Revenue (2020)

How Ernexa Therapeutics ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password